The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells

Jones, 1980, Cellular differentiation, cytidine analogs and DNA methylation, Cell, 20, 85, 10.1016/0092-8674(80)90237-8 Lübbert, 2001, Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine, Br J Haematol, 114, 349, 10.1046/j.1365-2141.2001.02933.x Silverman, 2002, Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B, J Clin Oncol, 20, 2429, 10.1200/JCO.2002.04.117 Wilson, 1983, Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2′-deoxycytidine as a possible mechanism of chemotherapeutic action, Cancer Res, 43, 3493 Daskalakis, 2002, Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment, Blood, 100, 2957, 10.1182/blood.V100.8.2957 Gore, 2006, Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms, Cancer Res, 66, 6361, 10.1158/0008-5472.CAN-06-0080 Hackanson, 2005, In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies, Ann Hematol, 84, 32, 10.1007/s00277-005-0004-1 Claus, 2005, Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents, Semin Oncol, 32, 511, 10.1053/j.seminoncol.2005.07.024 Scanlan, 2004, The cancer/testis genes: review, standardization, and commentary, Cancer Immun, 4, 1 Zendman, 2003, Cancer/testis-associated genes: identification, expression profile, and putative function, J Cell Physiol, 194, 272, 10.1002/jcp.10215 Fiszer, 1998, Major histocompatibility complex expression on human, male germ cells: a review, Am J Reprod Immunol, 40, 172, 10.1111/j.1600-0897.1998.tb00409.x Gnjatic, 2006, NY-ESO-1: review of an immunogenic tumor antigen, Adv Cancer Res, 95, 1, 10.1016/S0065-230X(06)95001-5 Jäger, 2000, Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses, Proc Natl Acad Sci USA, 97, 4760, 10.1073/pnas.97.9.4760 Nicholaou, 2006, Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1, Immunol Cell Biol, 84, 303, 10.1111/j.1440-1711.2006.01446.x Simpson, 2005, Cancer/testis antigens, gametogenesis and cancer, Nat Rev Cancer, 5, 615, 10.1038/nrc1669 Ross, 2005, The DNA sequence of the human X chromosome, Nature, 434, 325, 10.1038/nature03440 De Smet, 1996, The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation, Proc Natl Acad Sci USA, 93, 7149, 10.1073/pnas.93.14.7149 Karpf, 2004, Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine, Mol Pharmacol, 65, 18, 10.1124/mol.65.1.18 Weber, 1994, Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine, Cancer Res, 54, 1766 Weiser, 2001, Sequential 5-Aza-2′-deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1, J Immunother (1991), 24, 151, 10.1097/00002371-200103000-00010 Adair, 2009, Treatment of ovarian cancer cell lines with 5-aza-2′-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules, Cancer Immunol Immunother, 58, 589, 10.1007/s00262-008-0582-6 Coral, 2002, 5-Aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications, Clin Cancer Res, 8, 2690 Chambost, 2001, MAGE-A genes are not expressed in human leukemias, Leukemia, 15, 1769, 10.1038/sj.leu.2402278 Lim, 1999, Expression of testicular genes in haematological malignancies, Br J Cancer, 81, 1162, 10.1038/sj.bjc.6690824 Niemeyer, 2003, Expression of serologically identified tumor antigens in acute leukemias, Leuk Res, 27, 655, 10.1016/S0145-2126(02)00230-8 Sigalotti, 2003, 5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?, Blood, 101, 4644, 10.1182/blood-2002-11-3458 Claus, 2006, Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repression, J Leukoc Biol, 80, 1462, 10.1189/jlb.0106005 Riker, 2000, Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes, Int J Cancer, 86, 818, 10.1002/(SICI)1097-0215(20000615)86:6<818::AID-IJC10>3.0.CO;2-W Jäger, 2006, Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients, Proc Natl Acad Sci USA, 103, 14453, 10.1073/pnas.0606512103 Jäger, 2002, Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51, Cancer Immun, 2, 12 Fenaux, 2009, Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study, Lancet Oncol, 10, 223, 10.1016/S1470-2045(09)70003-8 Kantarjian, 2006, Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study, Cancer, 106, 1794, 10.1002/cncr.21792 Rüter, 2006, Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2′-deoxycytidine retreatment in high-risk myelodysplasia patients, Cancer, 106, 1744, 10.1002/cncr.21796 Pinto, 1984, Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2′-deoxycytidine, Lancet, 2, 867, 10.1016/S0140-6736(84)90900-0 Lübbert, 2003, Multiple hypermethylated genes are potential in vivo targets of demethylating agents, Blood, 101, 4645 Lübbert, 2009, Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting, Bone Marrow Transplant Graef, 2007, Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine, Leuk Res, 31, 257, 10.1016/j.leukres.2006.03.003 De Padua Silva, 2009, Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome, Bone Marrow Transplant, 43, 839, 10.1038/bmt.2008.400 Lübbert, 2009, Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients, Bone Marrow Transplant, 44, 585, 10.1038/bmt.2009.64 de Lima, 2003, Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias, Cancer, 97, 1242, 10.1002/cncr.11184 Rusakiewicz, 2006, Immunotherapeutic peptide vaccination with leukemia-associated antigens, Curr Opin Immunol, 18, 599, 10.1016/j.coi.2006.07.005 Hunder, 2008, Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1, N Engl J Med, 358, 2698, 10.1056/NEJMoa0800251 Coral, 2007, 5-AZA-2′-deoxycytidine in cancer immunotherapy: a mouse to man story, Cancer Res, 67, 2900, 10.1158/0008-5472.CAN-06-2986 Guo, 2006, De novo induction of a cancer/testis antigen by 5-aza-2′-deoxycytidine augments adoptive immunotherapy in a murine tumor model, Cancer Res, 66, 1105, 10.1158/0008-5472.CAN-05-3020 Schrump, 2006, Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura, Clin Cancer Res, 12, 5777, 10.1158/1078-0432.CCR-06-0669 Keith, 1986, Active X chromosome DNA is unmethylated at eight CCGG sites clustered in a guanine-plus-cytosine-rich island at the 5′ end of the gene for phosphoglycerate kinase, Mol Cell Biol, 6, 4122, 10.1128/MCB.6.11.4122 James, 2006, Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b, Oncogene, 25, 6975, 10.1038/sj.onc.1209678 Koslowski, 2006, The human X chromosome is enriched for germline genes expressed in premeiotic germ cells of both sexes, Hum Mol Genet, 15, 2392, 10.1093/hmg/ddl163 Cheng, 2004, Preferential response of cancer cells to zebularine, Cancer Cell, 6, 151, 10.1016/j.ccr.2004.06.023 Natsume, 2008, The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma, Int J Cancer, 122, 2542, 10.1002/ijc.23407